Pieris AG

Pieris was established in January 2001 with the vision of commercially exploiting technologies developed originally by Prof. Dr. Arne Skerra, Head of the Department of Biological Chemistry at the Technical University of Munich (TUM), Germany. While the scientific excellence of Prof. Dr. Skerra and his fellow Pieris co-founders has long been recognized by the academic community, the product commercialization potential of their discoveries was acknowledged through Pieris’ attainment in 2000 of first prize in the Munich Business Plan Contest. Based in facilities located at Freising-Weihenstephan, close to the TUM just north of Munich, Pieris has now grown to 29 employees with considerable experience and know-how in the engineering of novel proteins for development as diagnostic and therapeutic products. The Company was originally funded by seed venture capital from TransConnect and BioM. A subsequent €12 million Series A financing round in October 2002 included five new international life science investors; the round was co-led by Global Life Science Ventures and Gilde Investment Management B.V., together with BayTech Venture Capital, ABN AMRO Capital, BioM Venture Capital, and further investment by existing shareholder TransConnect. In addition to Series A Financing, mezzanine capital was raised from KfW and Bayernkapital.

Contact Details: Lise-Meitner-Straße 30 Freising-Weihenstephan 85354 Germany Tel: 49 (0) 8161 14 11 400 Fax: 49 (0) 8161 14 11 444 Email: info@pieris-ag.com WWW: www.pieris.biz/

Press Releases on Pieris AG:
Pieris Reports Preclinical Development Progress of its Next Generation VEGF Antagonist	9th October, 2009		FREISING-WEIHENSTEPHAN, Germany, October 9 /PRNewswire/ -- Pieris AG, the biopharmaceutical company developing Anticalins as a novel class of targeted human protein therapeutics, today reported
Pieris Reports Development Progress for Anticalin(R) PRS-050, a Next Generation VEGF Antagonist	3rd February, 2009		FREISING-WEIHENSTEPHAN, Germany, February 3 /PRNewswire/ -- Pieris AG, a biopharmaceutical company developing Anticalins(R), a novel class of targeted human protein therapeutics, reports today that it
Wacker Validates Scalability of Anticalin(R) Production With E.coli Secretion Technology and Will Produce Pieris First Clinical Candidate PRS-050	16th July, 2008		FREISING-WEIHENSTEPHAN and JENA, Germany, July 16 /PRNewswire/ -- Pieris AG, a bio-pharmaceutical company developing Anticalins(R), a novel class of targeted human protein therapeutics, and Wacker

BioNews Results for Pieris AG:
Allergan reports operating results for the third quarter of 2009	News-Medical.Net:  Oct 29 2009 2:00PM Matching: pieris ag
Pieris reports its progress in the development of PRS-050	News-Medical.Net:  Oct 12 2009 10:16AM Matching: pieris ag
Pieris Reports Preclinical Development Progress of its Next Generation VEGF Antagonist	Montana's News Station:  Oct 10 2009 3:52AM Matching: pieris ag
Pieris Reports Preclinical Development Progress of its Next Generation VEGF Antagonist	Pharma Live:  Oct 9 2009 8:53PM Matching: pieris ag
Pieris Reports Preclinical Development Progress of its Next Generation VEGF Antagonist	KLFY:  Oct 9 2009 7:58PM Matching: pieris ag
Promote your company here: BioNewsCast - Press Release Distribution	→View more Pieris AG news.

Pieris AG Patents:
US Patent No.	Title
7585940	Muteins of human tear lipocalin
7252998	Muteins of human neutrophil gelatinase-associated lipocalin and related proteins
7250297	Anticalins

Contact BioPortfolio for a quote for a customised Excel verision of BioCorporate or BioEmail databases.

This page has been viewed 475 times since April 2007, the link to the organisation's website has been followed 69 times

Recent Search Terms used to find this page: Arne Skerra pieris | Arne Skerra pieris | pieris pharma | pieris pharma | pieris munchen | pieris ag | pieris ag | Arne Skerra and patent | pieris Series A | arne skerra | .

Search for more companies in Freising-Weihenstephan

Search for more companies in

This site uses Thumbshots previews, resources from the NCBI applied. Maps are centred on zip/postcodes and should not be relied upon for exact building locations. Some information on this page has been collected automatically and may not have been verified.
BioPortfolio search results for Pieris AG